The integration of immunohistochemical (IHC) and molecular markers, such as vimentin, synaptophysin, and H3K27me, has significantly enhanced the ability to distinguish between different glioma subtypes, particularly oligodendrogliomas and diffuse midline gliomas (DMGs) [15,70]. The gene discussed is VIM; the disease is central nervous system cancer.